| Acquired by | Takeda Pharmaceutical |
| Price | $310M |
| Date | 12/11 |
| Website | intellikine.com |
| Category | BioTech |
| Phone | 858.768.6500 |
| Employees | |
| Description | Oncology Pharmaceuticals |
| Total | $85M |
| Series B, 6/07 Sofinnova Ventures | $30M |
| Series B, 7/09 Novartis Venture Funds US Venture Partners Biogen Idec Abingworth CMEA Capital Sofinnova Ventures | $51M |
| Unattributed, 10/11 | $4M |
Intellikine works in the discovery and development of novel, small molecule therapies targeting the PI3K/Akt/mTOR pathway.
Intellikine is committed to building an exceptional team and a powerful discovery platform that rapidly generates small molecule kinase inhibitor drug candidates that will become the next generation of medical breakthroughs.
